Medivation (NASDAQ:MDVN) is an oncology focused biotechnology company. Its only drug is an androgen receptor blocker called Xtandi, approved for treating metastatic castrate resistant prostate cancer (mCRPC) patients that have failed chemotherapy (post-chemo). The agent is undergoing Phase III development as treatment for mCRPC patients that have not received chemotherapy (pre-chemo). In addition, the compound is being evaluated in a Phase I study as treatment for breast cancer.
Xtandi's market launch in September 2012 followed that of Zytiga in May 2011. Both drugs treat post-chemo mCRPC patients. Moreover, both affect testosterone signaling, but through different mechanisms of action. Xtandi inhibits androgen receptor (NYSE:AR) activity at three steps: it prevents the binding of the testosterone with...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|